Merit Medical Systems, Inc. $MMSI Stock Position Cut by Conestoga Capital Advisors LLC

Conestoga Capital Advisors LLC lowered its stake in Merit Medical Systems, Inc. (NASDAQ:MMSI) by 4.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,086,483 shares of the medical instruments supplier’s stock after selling 98,782 shares during the quarter. Merit Medical Systems accounts for 3.1% of Conestoga Capital Advisors LLC’s portfolio, making the stock its 7th largest position. Conestoga Capital Advisors LLC’s holdings in Merit Medical Systems were worth $183,903,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Sowell Financial Services LLC boosted its stake in shares of Merit Medical Systems by 4.2% during the 3rd quarter. Sowell Financial Services LLC now owns 4,355 shares of the medical instruments supplier’s stock worth $362,000 after acquiring an additional 174 shares during the last quarter. Blue Trust Inc. boosted its stake in shares of Merit Medical Systems by 11.0% during the 4th quarter. Blue Trust Inc. now owns 1,853 shares of the medical instruments supplier’s stock worth $163,000 after acquiring an additional 184 shares during the last quarter. First Horizon Corp boosted its stake in shares of Merit Medical Systems by 19.7% during the 4th quarter. First Horizon Corp now owns 1,117 shares of the medical instruments supplier’s stock worth $98,000 after acquiring an additional 184 shares during the last quarter. CANADA LIFE ASSURANCE Co boosted its stake in shares of Merit Medical Systems by 0.4% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 50,667 shares of the medical instruments supplier’s stock worth $4,095,000 after acquiring an additional 189 shares during the last quarter. Finally, Palouse Capital Management Inc. boosted its stake in shares of Merit Medical Systems by 27.5% during the 3rd quarter. Palouse Capital Management Inc. now owns 1,076 shares of the medical instruments supplier’s stock worth $90,000 after acquiring an additional 232 shares during the last quarter. Hedge funds and other institutional investors own 99.66% of the company’s stock.

Merit Medical Systems Stock Performance

Shares of NASDAQ MMSI opened at $68.18 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.95 and a current ratio of 4.34. The company has a market cap of $4.07 billion, a P/E ratio of 32.16, a P/E/G ratio of 1.83 and a beta of 0.64. The firm’s fifty day moving average is $70.68 and its two-hundred day moving average is $79.78. Merit Medical Systems, Inc. has a 52-week low of $63.78 and a 52-week high of $100.19.

Merit Medical Systems (NASDAQ:MMSI) last announced its quarterly earnings results on Tuesday, February 24th. The medical instruments supplier reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.96 by $0.08. The company had revenue of $393.94 million for the quarter, compared to the consensus estimate of $390.77 million. Merit Medical Systems had a net margin of 8.48% and a return on equity of 13.82%. Merit Medical Systems’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.93 EPS. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. As a group, analysts anticipate that Merit Medical Systems, Inc. will post 3.61 EPS for the current fiscal year.

Analyst Ratings Changes

MMSI has been the topic of several analyst reports. Wall Street Zen cut shares of Merit Medical Systems from a “strong-buy” rating to a “buy” rating in a research note on Sunday, April 5th. Barrington Research decreased their price objective on shares of Merit Medical Systems from $109.00 to $107.00 and set an “outperform” rating on the stock in a research report on Monday, April 20th. Wells Fargo & Company downgraded shares of Merit Medical Systems from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $95.00 to $78.00 in a research report on Thursday, February 26th. Compass Point set a $107.00 price objective on shares of Merit Medical Systems in a research report on Monday, April 20th. Finally, Needham & Company LLC restated a “buy” rating and set a $101.00 price objective on shares of Merit Medical Systems in a research report on Wednesday, April 1st. Seven research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $99.56.

Key Headlines Impacting Merit Medical Systems

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Company raised FY2026 EPS guidance to a range of $4.010–$4.150, above sell?side consensus, signaling stronger-than-expected full-year profitability and giving investors forward visibility. Merit Medical Tops Q1 Forecasts, Raises 2026 Outlook
• Positive Sentiment: Underlying profitability metrics improved: non?GAAP EPS grew ~9%, non?GAAP operating margin ticked up to 19.7%, and free cash flow rose ~26% — all supportive for valuation and buy-side sentiment. Merit Medical Reports First Quarter 2026 Results and Updates Full-Year Guidance
• Positive Sentiment: Strategic M&A and portfolio actions: acquisition of View Point Medical for $140M (adds OneMark imaging/marker products) and sale of DualCap assets for $28M — moves that fund growth and improve product mix. Merit Medical Reports First Quarter 2026 Results and Updates Full-Year Guidance
• Neutral Sentiment: Top-line was mixed: reported revenue of $381.9M (+7% YoY constant currency) showed organic growth but came in below some market forecasts, creating both reassurance on growth and caution on near-term demand. Merit Medical: Q1 Earnings Snapshot
• Neutral Sentiment: Company reorganized revenue presentation into “Foundational” and “Therapeutic” categories to better reflect product uses — useful for long?term clarity but not an immediate earnings driver. Merit Medical Reports First Quarter 2026 Results and Updates Full-Year Guidance
• Neutral Sentiment: Analyst estimate changes were mixed heading into the quarter (Zacks issued both small raises and cuts across near-term estimates), so market reaction reflects a re?pricing around new company guidance rather than consensus convergence. Merit Medical (MMSI) Q1 Earnings and Revenues Beat Estimates
• Negative Sentiment: Some outlets noted the quarter missed certain street estimates (EPS and revenue vs some consensus figures), which creates headline risk and explains why reactions were mixed across reports despite the raised guidance. Merit Medical Systems Q1 Results and Call

About Merit Medical Systems

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.